Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature

Bari, Berardino De; Daidone, Antonino; Alongi, Filippo

doi:10.1016/j.critrevonc.2015.02.003

Cited by 28 publications

(17 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mature results from randomised trials of external beam radiotherapy (EBRT) show that biochemical control of disease improves with increasing radiation dose [1][2][3][4]. High-dose-rate afterloading brachytherapy (HDR-BT) can deliver a high, localised radiation dose to the prostate with excellent biochemical control of disease and has advantages over external beam radiotherapy (EBRT) because of its ability to overcome problems of organ movement, which confound the external beam techniques used [5][6][7] despite modern image guided approaches. In addition it can deliver dose in large fractions which is the most biologically efficient means of dose escalation in prostate cancer.…”

Section: Background and Purposementioning

confidence: 99%

Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results

Hoskin

Rojas

Ostler

et al. 2021

Radiotherapy and Oncology

View full text Add to dashboard Cite

Background and purpose: A randomised phase-III trial compared external beam radiotherapy (EBRT) alone with EBRT combined with high-dose-rate brachytherapy boost (HDR-BTb) in localised prostate adenocarcinoma. Previous analysis, at median follow up of 85 months, demonstrated improved relapse free survival (RFS) with EBRT + HDR-BTb. This data has now been updated with a median follow up of 131 months. Materials and methods: From December 1997 to August 2005, patients were assigned either to EBRT alone delivering 55 Gy in 20 fractions over 4 weeks or EBRT followed by a temporary high-dose-rate implant delivering 2 Â 8Á5 Gy over 24 h. The primary endpoint was RFS defined by a PSA rise !2.0 mg/l above nadir, clinical progression or death. Actuarial survival rates and Hazard Ratios (HRs) were calculated using the Kaplan-Meier method and Cox's Proportional Hazard Model, respectively. Secondary endpoints were overall survival (OS), urinary and bowel toxicity. Results: One hundred and six patients received EBRT alone and 110 EBRT + HDR-BTb. Median time to relapse was 137 months in the HDR-BTb arm compared to 82 months for EBRT alone (p = 0Á01). A 27% risk of recurrence with EBRT alone was observed (p = 0Á001), resulting in a 21% improvement in RFS at 12 years with EBRT + HDR-BTb. In multivariate analysis treatment arm, risk category and no androgen deprivation therapy were significant covariates for risk of relapse. Differences in overall survival were not significant. Conclusion: At 12 years there remains a significant improvement in RFS after EBRT + HDR-BTb; both treatments were equitoxic for severe late urinary and bowel events and urethral strictures.

show abstract

Section: Background and Purposementioning

confidence: 99%

Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results

Hoskin

Rojas

Ostler

et al. 2021

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…Мощность радиоактивных источников рассчитана таким образом, чтобы минимизировать возможность развития побочных эффектов в прилежащих тканях. Благодаря этому и интраоперационному моделированию зоны облучения возможно добиться разрушения раковых клеток, сохраняя при этом здоровые ткани и жизненно важные структуры, находящиеся вблизи ПЖ [16]. Данный метод применяется для лечения пациентов с РПЖ низкой степени риска [17][18][19].…”

Section: брахитерапияunclassified

Postoperative Complications of Minimally Invasive Therapies for Prostate Cancer

et al. 2018

View full text Add to dashboard Cite

Prostate cancer is the most common cancer among men. Radical prostatectomy (open, laparoscopic, or robotic) remains the main method of surgical treatment for prostate cancer. However, minimally invasive therapies for prostate cancer are becoming increasingly popular in recent years, because they have similar efficacy as open surgery. The most studied minimally invasive therapies are cryoablation, high intensity focused ultrasound (HIFU), and brachytherapy.Despite the minimization of damage to neighboring structures, minimally invasive procedures can cause a number of complications, like any other surgical interventions. Each method has specific limitations and the most typical complications. Since multiple minimally invasive methods are currently available, we can ensure an individual approach to each particular patient, thus using the advantages of the methods and avoiding possible complications. This article covers the most frequent and severe complications of minimally invasive therapies for prostate cancer, as well as the methods of their prevention and treatment.

show abstract

“…Interstitial brachytherapy (IBT) is a treatment option for a variety of tumor sites including, e.g., prostate [1], head and neck [2], breast [3], and gynecology [4]. Implantation of the needles/catheters (without loss of generality, all different types of needles or catheters will be referred to as catheters in this article, unless a differentiation is required) is patient specific and requires imaging such as computed tomography (CT), magnetic resonance imaging (MRI), transrectal ultrasound (TRUS), or conventional X-rays to determine the track of each implanted catheter, the so-called implant geometry.…”

Section: Purposementioning

confidence: 99%

Electromagnetic tracking for treatment verification in interstitial brachytherapy

Bert

Kellermeier

Tanderup

2016

jcb

View full text Add to dashboard Cite

Electromagnetic tracking (EMT) is used in several medical fields to determine the position and orientation of dedicated sensors, e.g., attached to surgical tools. Recently, EMT has been introduced to brachytherapy for implant reconstruction and error detection. The manuscript briefly summarizes the main issues of EMT and error detection in brachytherapy. The potential and complementarity of EMT as treatment verification technology will be discussed in relation to in vivo dosimetry and imaging.

show abstract

Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature

Cited by 28 publications

References 52 publications

Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results

Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results

Postoperative Complications of Minimally Invasive Therapies for Prostate Cancer

Electromagnetic tracking for treatment verification in interstitial brachytherapy

Contact Info

Product

Resources

About